|
|
|
Insider
Information: |
Bienaime Jean Jacques |
Relationship: |
|
City: |
Palo Alto |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
8 |
|
Direct
Shares |
540,054 |
|
Indirect Shares
|
247,533 |
|
|
Direct
Value |
$43,092,104 |
|
|
Indirect Value
|
$21,938,850 |
|
|
Total
Shares |
787,587 |
|
|
Total
Value |
$65,030,954 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
1
|
Stock
price went up :
|
1
|
0
|
Stock
price went down : |
1
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
Percentage
Gain/Loss : |
-13.1%
|
-5.5%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Biomarin Pharmaceutical Inc |
BMRN |
Director |
2024-05-20 |
473,792 |
2024-05-20 |
247,533 |
Premium* |
|
Neurogesx Inc |
NGSX |
Director |
2011-07-26 |
21,748 |
|
0 |
Premium* |
|
InterMune Inc |
ITMN |
Director |
2014-09-29 |
0 |
2012-04-06 |
0 |
Premium* |
|
Portola Pharmaceuticals Inc |
PTLA |
Director |
2014-05-16 |
706 |
2013-05-28 |
0 |
Premium* |
|
Immunic Inc |
IMUX |
Director |
2018-09-24 |
18,500 |
2001-04-23 |
0 |
Premium* |
|
Incyte Corp |
INCY |
Director |
2023-06-14 |
15,493 |
|
0 |
Premium* |
|
Immunome Inc. |
IMNM |
|
2024-05-21 |
9,615 |
|
0 |
Premium* |
|
Keros Therapeutics, Inc. |
KROS |
|
2024-06-01 |
200 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
853 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 21 of 35
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2017-06-01 |
4 |
OE |
$17.33 |
$86,650 |
D/D |
5,000 |
238,564 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2017-06-02 |
4 |
OE |
$17.33 |
$86,650 |
D/D |
5,000 |
238,564 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2016-11-22 |
4 |
OE |
$26.49 |
$1,847,492 |
D/D |
69,743 |
240,425 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2016-11-21 |
4 |
OE |
$26.49 |
$1,847,519 |
D/D |
69,744 |
240,426 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2015-05-12 |
4 |
D |
$121.09 |
$284,440 |
D/D |
(2,349) |
240,826 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2017-05-31 |
4 |
OE |
$17.33 |
$128,641 |
D/D |
7,423 |
240,987 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2015-05-08 |
4 |
D |
$121.66 |
$666,575 |
D/D |
(5,479) |
243,175 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2017-04-25 |
4 |
OE |
$17.33 |
$86,650 |
D/D |
5,000 |
243,194 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2017-04-27 |
4 |
OE |
$17.33 |
$86,650 |
D/D |
5,000 |
243,194 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2017-05-05 |
4 |
OE |
$17.33 |
$86,650 |
D/D |
5,000 |
243,496 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2017-05-08 |
4 |
OE |
$17.33 |
$86,650 |
D/D |
5,000 |
243,496 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2017-05-12 |
4 |
OE |
$17.33 |
$86,650 |
D/D |
5,000 |
243,496 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2023-02-07 |
4 |
GD |
$0.00 |
$0 |
I/I |
200 |
247,333 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2020-07-09 |
4 |
GD |
$0.00 |
$0 |
I/I |
425 |
247,533 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2015-05-01 |
4 |
AS |
$114.98 |
$402,992 |
D/D |
(3,505) |
248,654 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2018-03-15 |
4 |
D |
$83.57 |
$1,245,862 |
D/D |
(14,908) |
249,766 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2015-04-01 |
4 |
AS |
$120.53 |
$422,590 |
D/D |
(3,506) |
251,251 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2015-04-30 |
4 |
A |
$51.26 |
$46,547 |
D/D |
908 |
252,159 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2015-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
39,600 |
254,757 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2018-03-02 |
4 |
D |
$79.86 |
$682,164 |
D/D |
(8,542) |
264,674 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2018-03-15 |
4 |
AS |
$84.73 |
$1,270,901 |
D/D |
(15,000) |
264,674 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2020-03-13 |
4 |
D |
$84.50 |
$2,615,444 |
D/D |
(30,952) |
265,491 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2018-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
45,722 |
272,216 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2018-02-26 |
4/A |
A |
$0.00 |
$0 |
D/D |
46,034 |
272,528 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2018-03-02 |
4 |
OE |
$14.39 |
$14,390 |
D/D |
1,000 |
273,216 |
0 |
- |
|
853 Records found
|
|
Page 21 of 35 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|